2024-12-08 - Analysis Report
## Procter & Gamble Co (PG) Investment Report

**1. Performance Comparison & Summary:**

Procter & Gamble Co (PG) is a multinational consumer goods company that manufactures and markets a wide range of products.  Over the analyzed period, PG's cumulative return (86.48%) underperformed the S&P 500 (VOO) cumulative return (122.19%) by 35.7 percentage points.  This places its relative underperformance at the 9.5th percentile of its historical range (max: 38.9%, min: -43.5%).  While PG consistently shows positive alpha (0.1), indicating outperformance relative to the market, the underperformance versus the S&P 500 in this specific timeframe is notable.

**2. Recent Price Movement:**

* **Last Price:** $173.82
* **5-Day Moving Average:** $176.02
* **20-Day Moving Average:** $172.98
* **60-Day Moving Average:** $170.77

The price is currently below its 5-day moving average, suggesting a short-term bearish trend, but above its 20 and 60-day averages suggesting longer term support. The difference between the last market price ($173.84) and the reported closing price ($173.82) is negligible and doesn't indicate any significant immediate price changes.

**3. Technical Indicators & Expected Return:**

* **RSI:** 61.84 (Slightly above neutral, suggesting neither overbought nor oversold conditions)
* **PPO:** 0.0045 (Positive, indicating bullish momentum, but very weak)
* **Recent Relative Strength Change (20-day):** -9.3% (Short-term weakening)
* **Expected Return (vs. S&P 500, long-term):** 0.0% (This suggests that, based on the provided data, long-term investment in PG is not expected to significantly outperform the S&P 500).  Further analysis considering factors beyond the data provided would be needed for a more reliable prediction.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-10-18 | $1.65  | $21.74 B     |
| 2024-04-19 | $1.56  | $20.20 B     |
| 2024-01-23 | $1.44  | $21.44 B     |
| 2023-10-18 | $1.89  | $21.87 B     |
| 2024-10-18 | $1.89  | $21.87 B     | *(There appears to be a duplicate entry. We'll use only one.)*

**Analysis:**

* **Latest Quarterly Results:**  The most recent quarter (ending 2024-10-18) shows a significant drop in EPS ($1.65 vs $1.89 previously), despite relatively stable revenue.
* **Revenue Growth Trends:** Revenue fluctuates, showing no consistent upward or downward trend in the provided data.
* **EPS Trends:** EPS is volatile with notable decreases in the last two reported quarters.  Additional data is needed for a complete trend analysis.
* **Beats/Misses:**  No expectations data is provided, preventing an assessment of whether the results beat or missed expectations.


**5. Financial Information Analysis:**

**Revenue and Profitability:**

Revenue shows some fluctuation but remains largely stable around $21B. Profit margins are consistently high (around 50%), although there is some quarter-to-quarter variation.

**Capital and Profitability:**

Equity has been steadily increasing, indicating strong financial health. ROE, while generally high, experienced some volatility, particularly a notable dip in Q2 2024.


**6. News and Recent Issues:**

This section requires recent news articles and analyst reports to complete.  The provided data does not offer insights into recent market outlook, analyst opinions, or recent earnings news beyond the financial statements.

**7. Overall Analysis:**

PG has shown relatively stable revenue and high profit margins, indicative of a robust business model.  However, recent EPS performance displays concern.  Despite a generally positive alpha, its recent performance trails the S&P 500, and the provided data doesn't offer strong evidence for expecting future outperformance.  Additional information regarding market expectations, recent news, and a more comprehensive earnings history would provide a more thorough assessment.  The long-term outlook would require considering macroeconomic factors, competitor analysis, and future product development plans not included in this report.

**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  It is based solely on the limited data provided and should not be used as the sole basis for investment decisions. Consult with a qualified financial advisor before making any investment choices.
